GlyCardial Diagnostics
Spin-off company of the Catalan Institute of Cardiovascular Sciences (ICCC) and the Spanish National Research Council (CSIC) focused on the development of a novel in vitro diagnostic device for myocardial ischemia.
Launch date
Employees
Market cap
-
Enterprise valuation
$11—16m (Dealroom.co estimates Nov 2017.)
Company register number B67079186
Barcelona Catalonia (HQ)
- hard tech
- biotechnology
- horizon europe
- woman founder
- sustainable development goals
- spinout
- eit ecosystem
- cardiology
- eit health
- eit supernovas
- health it
- health diagnostics
- headstart (eit health)
- european health catapult (eit health)
- microbiology
- biomarkers
- headstart 2018 (eit health)
- european health catapult 2018 (eit health)
- caixa impulse (eit health)
- digital sandbox (eit health)
- digital sandbox 2020 (eit health)
- caixa impulse 2015 (eit health)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Revenues | - | <1m | <1m | <1m | <1m |
| % growth | - | - | 148 % | 108 % | 19 % |
| EBITDA | (<1m) | (<1m) | (<1m) | <1m | <1m |
| % EBITDA margin | - | (113 %) | (116 %) | 43 % | 34 % |
| Profit | (<1m) | (<1m) | (<1m) | (<1m) | (<1m) |
| % profit margin | - | (252 %) | (199 %) | (34 %) | (73 %) |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
€56.0k | Grant | ||
N/A | Spinout | ||
€2.4m | Series A | ||
N/A | Grant | ||
€50.0k | Grant | ||
€40.0k | Grant | ||
€1.9m | Grant | ||
$2.2m | Grant | ||
€30.0k | Grant | ||
| Total Funding | $7.1m | ||
Related Content
Recent News about GlyCardial Diagnostics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.